Impact of Cardiovascular Comorbidities on COPD Prognosis and Treatment Response: A Systematic Review
DOI:
https://doi.org/10.12775/QS.2026.68.74354Keywords
chronic obstructive pulmonary disease, Cardiovascular disease, treatment outcome, prognosis, comorbiditiesAbstract
Chronic obstructive pulmonary disease is commonly associated with co-existing cardiac disease, including ischemic heart disease, heart failure, hypertension and arrhythmias. Comorbidities are associated with the same risk factors as COPD; aging, systemic inflammation and smoking. There is now growing evidence that cardiac comorbidities impact the clinical course of COPD, leading to altered mortality, numbers of exacerbations and response to therapy. This systematic review aims to evaluate the impact of cardiovascular comorbidities on COPD prognosis and therapeutic outcomes.
References
[1]Schnell, K., Weiss, C.O., Lee, T. et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med 12, 26 (2012).
https://doi.org/10.1186/1471-2466-12-26
[2]Cronin E, Cushen B (January 2025). "Diagnosis and management of comorbid disease in COPD". Breathe (Sheffield, England). 21 (1): 240099
https://doi.org/10.1183/20734735.0099-2024
[3]https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
[4]Santos NCD, Miravitlles M, Camelier AA, et al. Prevalence and impact of comorbidities in individuals with chronic obstructive pulmonary disease: a systematic review. Tuberc Respir Dis (Seoul) 2022; 85: 205–220.
http://doi.org/10.4046/trd.2021.0179
[5]Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015 Aug;36(4):575-91. doi: 10.1055/s-0035-1556063. Epub 2015 Aug 3. PMID: 26238643; PMCID: PMC5004772.
https://doi.org/10.1055/s-0035-1556063
[6]Kaszuba E, Odeberg H, Rastam L, Halling A. Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study. BMC Fam Pract. 2018;19(1):178. https://doi.org/10.1186/s12875-018-0865-8
[7]Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice. J Clin Med. 2019 Jan 10;8(1):69. PMID: 30634565; PMCID: PMC6352261.
https://doi.org/10.3390/jcm8010069
[8]Miek Hornikx, Hans Van Remoortel, Heleen Demeyer, Carlos Augusto Marcal Camillo, Marc Decramer, Wim Janssens, Thierry Troosters. The influence of comorbidities on outcomes of pulmonary rehabilitation programs in patients with COPD: a systematic review. 2013
https://doi.org/10.1155/2013/146148
[9]André S, Conde B, Fragoso E, Boléo-Tomé JP, Areias V, Cardoso J; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and Cardiovascular Disease. Pulmonology. 2019 May-Jun;25(3):168-176. Epub 2018 Dec 7. PMID: 30527374.
https://doi.org/10.1016/j.pulmoe.2018.09.006
[10]Axson EL, Ragutheeswaran K, Sundaram V, Bloom CI, Bottle A, Cowie MR, Quint JK. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. 2020 Feb 14;21(1):54. doi: 10.1186/s12931-020-1312-7. PMID: 32059680; PMCID: PMC7023777.
https://doi.org/10.1186/s12931-020-1312-7
[11] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.
https://doi.org/10.1136/bmj.n71
[12] Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013 Oct;144(4):1163-1178. doi: 10.1378/chest.12-2847. PMID: 23722528.
https://doi.org/10.1378/chest.12-2847
[13]Vogelmeier CF, Friedrich FW, Timpel P, Kossack N, Diesing J, Pignot M, Abram M, Gediga M, Halbach M. Comorbidities and Cause of Death in COPD Patients Compared to Non-COPD Controls: An 8-year Observational Retrospective Healthcare Claims Database Cohort Study. Int J Chron Obstruct Pulmon Dis. 2025 Jun 27;20:2117-2130. doi: 10.2147/COPD.S488701. PMID: 40606812; PMCID: PMC12214430.
https://doi.org/10.2147/copd.s488701
[14]Noh E, Jeong H, Cho IS, Chang MS, Yu I, Park S, Lee JH, Lee SJ, Lee WY, Yong SJ, Kim SH. Risk of Cardiovascular Events Associated with Chronic Obstructive Pulmonary Disease and/or Metabolic Syndrome: A Large-Scale Nationwide Population-Based Cohort Study. Int J Chron Obstruct Pulmon Dis. 2024;19:1447-1456
https://doi.org/10.2147/COPD.S458779
[15]Caram LM, Ferrari R, Naves CR, Coelho LS, Vale SA, Tanni SE, Godoy I. Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD. J Bras Pneumol. 2016 May-Jun;42(3):179-84. doi: 10.1590/S1806-37562015000000121. PMID: 27383930; PMCID: PMC5569610.
https://doi.org/10.1590/s1806-37562015000000121
[16] Vasilis Nikolaou, Sebastiano Massaro, Wolfgang Garn, Masoud Fakhimi, Lampros Stergioulas, David Price,The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities,Respiratory Medicine,Volume 186,2021,106528,ISSN 0954-6111
https://doi.org/10.1016/j.rmed.2021.106528
[17]Wallström O, Stridsman C, Lindberg A, Nyberg F, Vanfleteren LEGW. Exacerbation History and Risk of Myocardial Infarction and Pulmonary Embolism in COPD. Chest. 2024 Dec;166(6):1347-1359. doi: 10.1016/j.chest.2024.07.150. Epub 2024 Jul 31. PMID: 39094732; PMCID: PMC11638550.
https://doi.org/10.1016/j.chest.2024.07.150
[18] Laura J. Spece, Eric M. Epler, Lucas M. Donovan, Matthew F. Griffith, Margaret P. Collins, Laura C. Feemster, David H. Au, Role of Comorbidities in Treatment and Outcomes after Chronic Obstructive Pulmonary Disease Exacerbations, Annals of the American Thoracic Society, Volume 15, Issue 9, September 2018, Pages 1033–1038,
https://doi.org/10.1513/AnnalsATS.201804-255OC
[19] Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-9. doi: 10.1016/S2213-2600(15)00241-6. Epub 2015 Jul 22. PMID: 26208998.
https://doi.org/10.1016/s2213-2600(15)00241-6
[20] Mannino DM, Davis KJ, Disantostefano RL. Chronic respiratory disease, comorbid cardiovascular disease and mortality in a representative adult US cohort. Respirology. 2013 Oct;18(7):1083-8. doi: 10.1111/resp.12119. PMID: 23683308.
https://doi.org/10.1111/resp.12119
[21]Sá-Sousa A, Rodrigues C, Jácome C, Cardoso J, Fortuna I, Guimarães M, Pinto P, Sarmento PM, Baptista R. Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review. J Clin Med. 2024 Aug 31;13(17):5173. . PMID: 39274386; PMCID: PMC11396696.
https://doi.org/10.3390/jcm13175173
[22]Baty F, Putora PM, Isenring B, Blum T, Brutsche M (2013)Comorbidities and Burden of COPD: A Population Based Case-Control Study. PLOS ONE 8(5):e63285.
https://doi.org/10.1371/journal.pone.0063285
[23]Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61. Epub 2012 May 3. PMID: 22561964.
https://doi.org/10.1164/rccm.201201-0034oc
[24]Ford ES, Wheaton AG, Mannino DM, Presley-Cantrell L, Li C, Croft JB. Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007-2010. Respir Res. 2012 Dec 13;13(1):115. PMID: 23237325; PMCID: PMC3546884.
https://doi.org/10.1186/1465-9921-13-115
[25]Laurent Laforest, Nicolas Roche, Gilles Devouassoux, Manon Belhassen, Christos Chouaid, Marine Ginoux, Eric Van Ganse,Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study,Respiratory Medicine,Volume 117,2016,Pages 33-39,ISSN 0954-6111,
https://doi.org/10.1016/j.rmed.2016.05.019
[26]Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013 Sep;107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001. Epub 2013 Jun 19. PMID: 23791463.
https://doi.org/10.1016/j.rmed.2013.05.001
[27]Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 Nov;104(22):1850-1858. doi: 10.1136/heartjnl-2017-312735. Epub 2018 Jun 6. PMID: 29875139.
https://doi.org/10.1136/heartjnl-2017-312735
[28]Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, Chaudhuri N, Schelbert EB, Potluri R, Miller CA. Association of Cardiovascular Disease With Respiratory Disease. J Am Coll Cardiol. 2019 May 7;73(17):2166-2177. doi: 10.1016/j.jacc.2018.11.063. Epub 2019 Mar 4. PMID: 30846341.
https://doi.org/10.1016/j.jacc.2018.11.063
[29]Cho EE, Maclagan LC, Chu A, Croxford R, Sin DD, Udell JA, Lee D, Austin PC, Gershon AS. Impact of COPD on cardiovascular risk factors and outcomes in people with established cardiovascular disease. Thorax. 2025 Apr 15;80(5):291-299. doi: 10.1136/thorax-2023-220991. PMID: 40032508.
https://doi.org/10.1136/thorax-2023-220991
[30]Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res. 2020 Feb;7(1):e000470. doi: 10.1136/bmjresp-2019-000470. PMID: 33371008; PMCID: PMC7011896.
https://doi.org/10.1136/bmjresp-2019-000470
[31]Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, Rutten EP, Op 't Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35. doi: 10.1164/rccm.201209-1665OC. PMID: 23392440.
https://doi.org/10.1164/rccm.201209-1665oc
[32]Tang M, Wang Y, Wang M, Tong R, Shi T. Risk for Cardiovascular Disease and One-Year Mortality in Patients With Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea Syndrome Overlap Syndrome. Front Pharmacol. 2021 Oct 26;12:767982. doi: 10.3389/fphar.2021.767982. PMID: 34764876; PMCID: PMC8576345.
https://doi.org/10.3389/fphar.2021.767982
[33]Ding Y, Hu J, Yu C, Sun D, Pei P, Yang L, Chen Y, Du H, Zhang Z, Barnard M, Chen J, Chen Z, Li L, Lv J. Long-term cardiovascular risk after severe exacerbation of COPD: a population-based cohort study. ERJ Open Res. 2026 Mar 16;12(2):00939-2025. doi: 10.1183/23120541.00939-2025. PMID: 41846685; PMCID: PMC12991000.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dominik Chrzanowski, Wiktoria Bajek Bajek, Daria Valipur Kolti Valipur, Mikołaj Lewandowski Lewandowski, Karolina Rymska Rymska, Marcelina Kaczmarek Kaczmarek, Alicja Serafin Serafin, Maciej Krzesimir Kuświk Kuświk, Kinga Żmuda Żmuda, Jakub Andrzejewicz Andrzejewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 113
Number of citations: 0
